Funding for this research was provided by:
Universitätsklinikum Bonn
Article History
Received: 30 June 2021
Revised: 28 September 2021
Accepted: 15 October 2021
First Online: 28 October 2021
Change Date: 19 February 2022
Change Type: Update
Change Details: Open Access funding enabled and organized by Projekt DEAL has been added as funding statement.
Declarations
:
: The research was conducted in adherence to tenets of the Declaration of Helsinki. Ethics Board Approval of the University of Bonn was granted (328/16).
: AC: None.FGH: Research funding and consulting: Genentech/Roche, Bayer, Boehringer-Ingelheim, Novartis, Allergan, Heidelberg Engineering; Beratung von Apellis, Lin BioScience; Research funding: Nightstar, CenterVue, Optos, Acucela, Alcon; Advisory Boards: Acucela, Allergan, Avalanche, Bayer, Genentech, Heidelberg Engineering, Johnson & Johnson, Lin BioScience, Novartis, Ophthotech, Roche, Oxurion.KUL: None.MCH-C: Research funding received from EPIC-XS and the German Research Foundation (HE5775/5–1) and consulting fees from GlakoSmithKline.